Farmacia Hospitalaria December 2025

Title	Farmacia Hospitalaria December 2025
Edition	December 2025
Call Number
ISBN/ISSN
Author(s)
Subject(s)	Heart Failure Cost-utility analysis Markov chain model Inpatients
Classification
Series Title
GMD	Jurnal
Language	Indonesia
Publisher	Farmacia Hospital
Publishing Year	2025
Publishing Place	Spanyol
Collation
Abstract/Notes	Introduction: Heart failure is an increasingly common syndrome with a rising prevalence, which associates significant costs, mainly related to hospitalization. In fact, heart failure is the most frequent diagnosis in hospital discharges in Spain. Objective: To analyze the economic impact of new treatments for heart failure with reduced ejection fraction such as sacubitril/valsartan in out-patient and in-patient setting. Material and methods: The present economic evaluation study was carried out by developing a Markov model. Treatment with sacubitril/valsartan from admission or after hospital discharge was compared, with enalapril being the comparator. Total costs, years of life gained, quality-adjusted life years, and incremental cost- effectiveness ratio and incremental cost-utility ratio were analyzed. Data were obtained from the PARADIGM- HF and PIONEER-HF studies. Results: The results of the base cases of the three comparisons made showed that sacubitril/valsartan produced benefits in years of life gained and quality-adjusted life years compared to enalapril showing incremental cost- utility ratio below €20,000/QALY and that this ratio was better in scenarios starting sacubitril/valsartan in the hospital setting once decompensation was resolved.
Specific Detail Info
Image
File Attachment	LOADING LIST...
Availability	LOADING LIST...
	Back To Previous